The veligrotug trial reveals a 2.9 mm reduction in proptosis for thyroid eye disease patients, offering a new FDA‑approved option beyond teprotumumab.
Musculoskeletal toxicities, including myalgias and arthralgias, impact up to 40% of patients on BTK inhibitors with muscle and joint pain.
Dr. Nadege Gunn outlines a tiered algorithm for MASH screening using the FIB-4 score, a simple calculation using AST, ALT, platelets, and…
Explore growing options for second-line therapy as clinicians tailor treatments to patient needs and preferences.
Hospital financial assistance documents often exceed the reading level of most Americans, leaving critical aid inaccessible. Learn why readability matters.
Clinical data silos hinder healthcare professionals, making it difficult to access information, with companies like Emtelligent working to change this with clin
Learn how a policy breach can block user access and impact financial performance in healthcare, with key strategies to prevent fraud and…